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Purpose: This study reports the initial and late results of percutaneous transluminal 
angioplasty (PTA) and intravascular stenting for atherosclerotic o clusive disease of the 
iliac arteries. 
Methods: The preprocedural nd postprocedural clinical records, arteriograms, segmental 
limb pressure measurements (ankle-brachial [ABI] and thigh-brachial [TBI] indexes), 
and pulse volume recordings of 288 patients who underwent PTA and primary stenting 
of the common iliac (354, 69.4%) and external lilac (156, 30.6%) arteries were reviewed. 
Initial and late clinical, hemodynamic, and angiographic success were assessed by objec- 
tive criteria. Data on patients who underwent unsuccessful attempts at iliac stent place- 
ment are unavailable; results are not reported on an intent-to-treat basis. 
Results: Clinical follow-up data (mean, 11.9 months) are available for 268 of 288 patients 
(93.1%) and for 394 of 424 limbs (92.9%). The initial success rates, as determined by 
TBI, ABI, and clinical limb status, were 90.2%, 87.8%, and 74.6%, respectively. The 
Kaplan-Meier estimates of angiographic patency (101 arteries) were 96%, 81%, and 73% 
at 6, 12, and 24 months. Cumulative patency rates were 84%, 76%, and 57% on the basis 
of TBI, ABI, and clinical limb status at 24 months. Factors associated with initial success 
included the need for multiple stents (p = 0.0001), a higher degree of initial stenosis (p = 
0.0001), lower severity of baseline ischemia (p = 0.007), younger age (p = 0.0015), and 
the preprocedural patency of the ipsilateral superficial femoral artery (p = 0.002). A 
higher degree of initial stenosis (p < 0.001) and superficial femoral artery patency (p = 
0.004) were also associated with late success. 
Conclusions: PTA and stenting of the iliac arteries is associated with reasonable angio- 
graphic, hemodynamic, and clinical success. The outcome is favorably affected by higher 
initial severity of stenosis and greater extent of disease, lower severity of baseline 
ischemia, younger age, and by patency of the ipsilateral superficial femoral artery. (J Vase 
Surg 1997;25:829-39.) 
Despite the reasonable success rates that have 
been reported for balloon angioplasty alone in the 
treatment of  atherosclerotic occlusive disease of  the 
aortoiliac segment, the use ofintravascuiar stents has 
been advocated to improve on these results. From 
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mid-1991 it has been our policy to treat atherosclc- 
rotic lesions of the iliac arteries with percutaneous 
transluminal angioplasty (PTA) and primary stent- 
ing, rather than reserving the use of stents for failed 
or unsatisfactory PTA, under the premise that the 
perceived immediate improvement in cosmetic and 
hemodynamic results achieved in the interventional 
laboratory would translate into improved clinical re- 
suits in both the short term and the long term. 
The primary goals of this study were to estimate 
the early and late failure rates of PTA and primary 
stenting of  the iliac arteries and to estimate the effect 
of various baseline patient and procedural character- 
istics on success or failure. For the iliac arteries, 
patency is most often assessed through clinical exam- 
ination by evaluating the degree of chronic limb 
ischemia, the presence or absence of  an ipsilateral 
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Table I. Descriptive information on 288 
patients (424 limbs) who underwent PTA 
and primary iliac artery stenting 
Characteristic n (%) 
Gender 
Male 
Female 
Diabetes mellitus 
Insulin-dependent 
Non-insulin- dependent 
Current tobacco use 
Hypertension 
Abnormal result of electrocardiogram 
History of myocardial nfarction 
History of congestive h art failure 
Current angina pectoris 
History of stroke 
Clinical limb status before intervention 
Claudication 
Limb-threatening ischemia 
Rest pain 
Necrosis 
Total 
178 (61.8) 
110 (38.2) 
45 (15.6) 
57 (19.8) 
132 (45.8) 
195 (67.7) 
145 (50.3) 
88 (28.8) 
41 (14.2) 
4o (13.9) 
29 (10.1) 
306 (72.2) 
66 (15.6) 
52 (12.2) 
424 limbs (100) 
femoral pulse, and through noninvasive vascular lab- 
oratory examination (segmental limb pressure mea- 
surements, including ankle-brachial indexes [ABIs], 
thigh-brachial indexes [TBIs], and pulse volume re- 
cordings). Angiographic follow-up may also be avail- 
able in selected patients who return for another diag- 
nostic or interventional procedure or who have 
symptomatic recurrence within or adjacent o the 
stented segment. Because of the limitations of non- 
invasive vascular laboratory examination and clinical 
evaluation in estimating the patency of procedures 
performed within the aortoiliac segment, because of  
the dissimilarities in reported "patency" rates for iliac 
interventions, and because of ethical and economic 
issues related to routine arteriographic surveillance of 
these interventions, we have chosen to report our 
results on the basis of a number of accepted criteria ~-3 
and to highlight their differences in estimating suc- 
cess or failure. 
PATIENTS AND METHODS 
From June 1991 to December 1995, we per- 
formed lilac artery angioplasty and primary intravas- 
cular stent placement in 288 patients (178 men 
[61.8%] and 110 women [38.2%]; mean age, 63.2 
years). All procedures were performed in an an- 
giography suite, with the patient under local anes- 
thesia, and with conscious sedation. Stents were 
placed percutaneously through a retrograde ipsi- 
lateral femoral artery puncture through 7F or 8F 
sheaths. After diagnostic angiographic examina- 
tion, the iliac lesion was traversed and transste- 
notic pressure gradients were measured. Patients 
were systemically anticoagulated with heparin so- 
dium, as measured by the activated clotting time. 
PTA and primary stent placement were performed 
with standard angioplasty balloons and either bal- 
loon-expandable Palmaz stents (Johnson and 
Johnson Interventional Systems, Warren, N.J.) in 
437 of  510 arteries (85.7%) or self-expanding 
Wallstents (Schneider, Inc., Minneapolis, Minn.) 
in 73 arteries (14.3%), at the discretion of the 
operator. The procedure was terminated when 
both angiographic success (brisk flow through the 
target vessel without evidence of thrombus or dis- 
section, residual stenosis <30%) and hemody- 
namic success (resting transstenotic pressure gradi- 
ent <5 mm Hg) had been achieved. Patients 
continued to take aspirin, but did not take heparin 
or warfarin, after the procedure; most patients 
were discharged after an overnight hospital stay. 
Basic data on all patients who underwent success- 
ful iliac angioplasty and stent placement during this 
time period were prospectively captured in a vascular 
registry. Data on those patients who underwent un- 
successful attempts at iliac stent placement are un- 
available, and as such, results are not reported on an 
intent-to-treat basis. The preprocedural and postpro- 
cedural clinical records, arteriograms, segmental 
limb pressure measurements, and pulse volume re- 
cording results were then retrospectively reviewed 
for the purpose of this study. Sixteen baseline pa- 
tient-specific, limb-specific, and procedural- or ar- 
tery-specific factors were studied to determine their 
effect on initial and late failure. These included age, 
presence of diabetes mellitus, gender, smoldng status 
(current vs other), presence of hypertension, history 
of congestive heart failure, serum creatinine level, 
severity of baseline ischemia (claudication vs ischemic 
rest pain vs tissue loss), degree of initial arterial ste- 
nosis, maximum balloon size used for dilatation, type 
ofstent (Wallstent vs Palmaz), maximum number of 
stents required per limb (one vs more than one), 
degree of residual stenosis after PTA and stent place- 
ment, patency of the ipsilateral superficial femoral 
artery (SFA), patency of the ipsilateral profunda fem- 
oris artery, and anatomic artery treated (common 
iliac vs external i iac). Descriptive information on the 
study group, including patient characteristics, pre- 
procedural limb status, and arteries treated, is listed 
in Tables I and II. One stent was placed in 62.3% of 
the 424 limbs, and more than one stent was placed in 
37.7%. 
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Table I I ,  A. Arteries treated with PTA and 
primary intravascular stenting 
Artery n % 
Common iliac 
Right 182 35.7 
Left 172 33.7 
External iliac 
Right 73 14.3 
Left 83 16.3 
Total 510 100 
Table I I ,  B. Initial stenosis by decile 
Stenosis (%) n (%) 
<49 30 (5.9) 
50-59 79 (15.5) 
60-69 69 (13.5) 
70-79 94 (18.4) 
80-89 86 (16.9) 
90-99 101 (19.8) 
Occlusion 51 (10.0) 
Total 510 (100) 
Definit ion of  outcomes 
Because of the limitations of clinical and noninva- 
sive follow-up in evaluating interventions on the iliac 
arteries, each intervention is assessed on a per-limb 
basis using several hemodynamic and clinical criteria. 
Each patient may have either one or both limbs 
included in the study, with each limb followed from 
the time of the incident procedure to the time of a 
second procedure (interventional or surgical) on that 
artery or to the time of last follow-up. Determina- 
tions of success and failure are based on the sug- 
gested standards for reports that deal with lower 
extremity ischemia published by Rutherford et al.l-3 
Detailed definitions of outcome are as follows: 
Immediate  clinical success. Immediate clinical 
success was defined from the first available clinical 
follow-up subsequent to the procedure. Success is 
determined by an increase of at least one clinical 
category of  chronic limb ischemia from baseline. 
Those patients who had actual tissue loss must have 
advanced at least wo clinical categories and reach the 
level of claudication to be considered improved. 
Late dinical success. Late clinical success was 
defined from the most recent clinical follow-up and 
by the presence or absence of a subsequent proce- 
dure to that limb. Success is defined as either no 
change or an improvement in limb status (from the 
first postprocedure clinical follow-up), whereas fail- 
ure is defined as a worsening in limb status. I f  a 
second procedure is performed on the same limb, 
clinical follow-up for that side concludes at that point 
because future changes in clinical limb status may be 
attributable to the second procedure. I f  the second 
procedure involves the originally stented segment, 
then the initial procedure on that side (limb) is clas- 
sified as a failure. If, however, the second procedure 
is to a different artery or to an arterial segment prox- 
imal or distal to the original stent (within the same 
anatomic artery), that limb is censored and classified 
as a success up to the date of the second procedure. 
Immediate  hemodynaic  success (by ABI  and 
Table I I ,  C. Number of arteries treated 
per patient 
No. per patient n (%) 
1 135 (44.9) 
2 131 (43.5) 
3 27 (9.0) 
4 8 (2.7) 
TB I  separately). Immediate hemodynamic success 
was defined from the first clinical follow-up subse- 
quent to the procedure. Success is determined by an 
increase in ABI or TBI of 0.10 or more from base- 
line. 
La te  hemodynamic  success (by ABI  and TBI  
separately). Late hemodynamic success was defined 
as either no change or an increase in ABI or TBI 
from the first postprocedural examination, or a de- 
crease of less than 0.15. 
Late angiographie success. Late angiographic 
success was defined from the latest angiographic fol- 
low-up and by the presence or absence of a subse- 
quent procedure performed on that artery. The crite- 
rion for success is stenosis <50%. Failure is defined as 
progression to stenosis ->50% or a repeat procedure 
performed on that segment. I f  a second procedure is
performed on the same anatomic artery proximal or 
distal to the index stent, that artery is censored and 
classified as a success up to the date of the new 
procedure. Percent restenosis was determined by 
comparing 'the minimal uminal diameter within the 
stented segment with the diameter of normal adja- 
cent artery using hand-held calipers. 
Statistical methods 
Estimates of the "survival" time were calculated 
using the method of Kaplan and Meier. 4 The rela- 
tionships between various factors and immediate 
clinical success were assessed using generalized esti- 
mating equation methods s,6 for correlated ichoto- 
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Table III, A. Early results of PTA and 
primary stenting ofiliac arteries based on 
hemodynamic and clinical criteria in 
424 limbs 
Immediate postprocedure Initial success 
follow-up (%) 
ABI (370) 325 (87.8) 
TBI (357) 322 (90.2) 
Limb status (390) 291 (74.6) 
Table III, B. Late results of PTA and 
primary stenting ofiliac arteries based on 
hemodynamic and clinical criteria in 
424 limbs 
At last follow-up Late patency 
(mean, 11.9 months) (%) 
ABI (230) 192 (83.5) 
TBI (229) 197 (86.0) 
Limb status (233) 158 (67.8) 
mous data. Using this method is analogous to using 
ordinary logistic regression but takes into account 
the correlation among multiple observations per pa- 
tient. The relationships between factors and late clin- 
ical and angiographic outcomes were assessed using 
proportional hazards regression models, which ad- 
just for the correlation among multiple observations 
per patient. "Survival" time was defined as the time 
(in months) from the initial procedure until either a 
second procedure or until last follow-up. To adjust 
for the multiple endpoints studied, only p values of 
0.01 or lower were considered statistically signifi- 
cant. 
RESULTS 
The initial and long-term results of PTA and 
primary stenting of the iliac artery were assessed by 
clinical, hemodynamic, and angiographic criteria on 
a per-limb basis. Clinical follow-up is available for 
268 of 288 patients (93.1%) and for 394 of 424 
limbs (92.9%) at a mean of 11.9 months (range, 0.1 
to 45 months). Initial success and late patency (at last 
clinical follow-up) data are summarized in Table III. 
Those variables found to be associated with initial 
and late failure are shown in Table IV. In addition, 
although it was not statistically significant, proce- 
dures on the external iliac artery approached the 
significance l vel ofp = 0.01 for late failure as mea- 
sured by TBI (risk ratio, 3.58; 95% confidence inter- 
val, 1.34 to 9.57; p = 0.012) when compared with 
the common iliac artery. Life table estimates of pa- 
tency rates are reported in Figs. 1 through 3. The 
patency rates at 6, 12, and 24 months were 96%, 
89%, and 76% when measured by ABI; 98%, 93%, 
and 84% by TBI; and 89%, 76%, and 57% when 
measured by improvement in clinical limb status. 
Documentation of a pulse examination by a staff 
physician at last follow-up (mean, 8.1 months; range, 
0.1 to 44 months) is available for 206 limbs. The 
ipsilateral femoral pulse was present in 196 of 206 
limbs (95.1%) at the time of last follow-up. 
Angiographic follow-up data are available fbr 64 
of 288 patients (22.2%) and for 101 of 510 stented 
arteries (19.8%) at mean follow-up of 10.5 + 11.3 
months (range, 0.1 to 40 months). Seventy arteries 
(69.3%) remained patent as of last follow-up, 
whereas the remainder either restenosed, occluded, 
or required arepeat procedure. These data are sum- 
marized in Table V. Life table estimates ofpatency at 
6, 12, and 24 months by angiographic analysis were 
96%, 81%, and 73%, respectively (Fig. 4). 
Complications occurred in 14.1% of 312 proce- 
dures and are listed in Table VI. Five patients went 
on to surgical aortofemoral reconstruction at a mean 
of 6.0 months after stent placement. Six patients 
underwent femorofemoral bypass procedures based 
on the ifiac stent as inflow, five immediately after 
stent placement and one 35 months after stenting. 
Finally, 32 patients underwent an infrainguinal by- 
pass procedure ipsilateral to the stented iliac segment 
(mean, 4.8 months; range, 0 to 30.1 months after 
stent placement). 
DISCUSSION 
Since their inception in the 1960s and 1970s, 7-11 
transluminal methods of treating occlusive arterial 
lesions have gained in popularity and scope, in part 
because of their relatively noninvasive nature and 
because of their perceived high rates of success when 
compared with standard surgical revascularization 
procedures. The iliac arteries, in particular, lend 
themselves toundergoing PTA because of their sub- 
stantial diameter, high flow, and ease of access 
through the ipsilateral femoral artery. According to a 
few studies reporting 3-year to 5-year results for 
angioplasty of the iliac arteries, patency rates range 
from 78% to 93% at 1 year, 65% to 89% at 3 years, 
and 59% to 87% at 5 years? 2d~ 
The data presented by Johnston et al. 12,16are 
noteworthy in that they are prospective and are ana- 
lyzed with contemporary statistical methods using 
strict clinical and hemodynamic criteria. For 667 
procedures on the iliac arteries, these authors report 
high rates of initial technical success (overall, 96.5%); 
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Fig. 1. Late patency data according to ABI on the basis of follow-up on 230 sides with 29 
failures. 
Table IV. Factors associated with initial and late failure ofiliac PTA and primary stenting, as 
measured by ABI, TBI, and clinical limb status 
Estimated 95% Confidence 
Factor risk ratio interval p 
Initial failure 
By ABI: 
Higher level of baseline ischemia 1.46 1.11 to 1.92 0.007 
Need for multiple stents 0.18 0.09 to 0.36 0.0001 
Occluded ipsilateral SFA 4.96 2.54 to 9.68 0.0001 
By TBh 
Occluded ipsilateral SFA 6.72 2.44 to 18.47 0.0002 
By limb status: 
Age (continuous, by decile) 1.50 1.17 to 1.94 0.0015 
Higher degree of initial stenosis 0.97 0.96 to 0.98 0.0001 
(continuous, 0-100%) 
Occluded SFA runoff 3.96 2.23 to 7.03 0.0001 
Late failure 
By limb status: 
Higher degree of initial stenosis 0.983 0.974 to 0.991 <0.001 
Occluded ipsilateral SFA 2.438 1.326 to 4.497 0.004 
the success rate for treating iliac artery stenoses 
(98.6%) was significantly better than for occlusions 
(81.9%). The 3-year success rates for iliac PTA 
ranged from 30% to 73%, depending on several vari- 
ables, including anatomic location of the treated le- 
sion, the nature of  the lesion (occlusion vs stenosis), 
the number of  lesions treated, gender, and runoff. 
The worst results were obtained for complete occlu- 
sions treated in conjunction with a tandem lesion, for 
external i iac lesions in women, and for patients with 
poor runoff. Johnston and his associates concluded 
that iliac PTA should be considered if the chances of 
long-term success are good. Their late success rates 
are lower than those reported in other series, likely 
because of the careful, objective methods that were 
used in their analysis and because both clinical and 
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Fig. 2. Late patency data according to TBI on the basis of follow-up on 229 sides with 23 
failures. 
hemodynamic mprovement were required for suc- 
cess. 
Despite reasonable' success rates, problems re- 
main with balloon angioplasty, including abrupt clo- 
sure, dissection, and difficulty treating heavily calci- 
fied lesions and total occlusions. Intravascuiar stents 
were designed to improve on the results of PTA by 
acting as a "scaffold" that tacks the damaged intima 
and media against the adventitia, away from the arte- 
rial lumen. The concept of an intraluminal stent was 
first proposed by Dotter and Judkins 7 in 1964; they 
speculated that an endovascuiar splint could main- 
tain vessel patency until endothelialization could take 
place. 
Palmaz et al. 17 have reported the results of a 
4-year muiticenter t ial of the Palmaz stent for iliac 
artery lesions in 486 patients and 567 limbs. Sus- 
tained clinical benefit was obtained in 90.9% at 1 
year, 84.1% at 2 years, and 68.6% at 43 months; the 
angiographic patency rate was 92% at 8.7 months. 
Murphy et al) s have reported on the long-term re- 
suits ofPalmaz stent placement in the iliac arteries in 
83 patients (103 limbs). Clinical patency was primar- 
ily determined by the degree of chronic lower ex- 
tremity ischemia, a consideration that took prece- 
dence over noninvasive studies when a discrepancy 
existed. Immediate clinical success was obtained in 
98.9%, with 86.2% remaining successful at 4 years by 
Kaplan-Meier estimation. The primary patency rate 
by arteriographic examination (30 patients; mean 
follow-up, 10.4 months) was 87.5%, with five occlu- 
sions (12.5%) and two restenoses >50% (5.0%). 
A multicenter t ial 19 of the self-expanding Wall- 
stent in the iliac and femoral arteries reported on 171 
lesions (163 limbs) in the iliac arteries alone. The 
immediate clinical patency rate by limb status was 
95%; the primary patency rates were 87% at 6 
months, 81% at 1 year, and 71% at 2 years. The 
arteriographic patency rate was 93% at a mean fol- 
low-up interval of  9.4 months.Using the same stent, 
Murphy et al. 2° treated 94 limbs in 66 patients, 
including 42 with diffuse iliac disease and 39 with 
chronic occlusions. These authors reported an initial 
clinical success rate by limb status of 85%, with cu- 
mulative primary patency rates of 78% at 1 year and 
53% at both 2 and 3 years. Preliminary results of a 
randomized muiticenter trial that compared PTA 
alone with PTA and stenting for iliac lesions suggest 
that the addition of stents improves the immediate 
hemodynamic and clinical results ofiliac intervention 
and may also favorably affect late patency rates and 
the need for reintervention to the treated segment. 21 
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Fig. 3. Late patency data according to limb status on the basis of follow-up on 233 sides with 
66 failures. 
However, although these data are available in the 
form of  an abstract, no formal report has yet been 
published. 
Either Palmaz stents or Wallstents were used, at 
the discretion of the primary operator, in this series. 
Although no strict criteria or protocol was used for 
determining which type of stent to use, each has its 
merits in particular situations. Factors that favor the 
use of the Palmaz balloon-expandable st nt include 
ease and accuracy of delivery through the ipsilateral 
femoral approach, suitability for use in treating short 
lesions (it is available in lengths from 10 mm to 39 
ram), and a perceived superiority in radial strength, 
making it useful in treating calcific lesions. The self- 
expanding Wallstent, because of its flexible nature, 
can be more easily delivered over the aortic bifurca- 
tion from the contralateral femoral approach and is 
well-suited to treating tortuous vessels. Because of its 
length, it can be used to treat longer lesions while 
using a single stent. Finally, because it is self-expand- 
ing, it can be used to treat lesions that encompass 
contiguous vessels of  different diameter, such as le- 
sions that involve both the common and external 
iliac arteries. 
The failure Of adherence to uniform reporting 
standards and the lack of long-term objective fol- 
low-up has made interpretation of the results of pe- 
Table V. Angiographic follow-up (mean, 
10.5 months) for 101 iliac arteries after PTA 
and primary intravascular stenting 
Angiographic status at last 
follow-up n (%) 
0% to 49% stenosis 70 (69.3) 
50% to 99% stenosis 3 (3.0) 
100% (occluded) 6 (5.9) 
Redo (PTA) to stented segment 10 (9.9) 
Redo to adjacent segment 12 (11.9) 
Total 101 (100) 
ripheral vascular interventions difficult at best. 2 Al- 
though most of the recent literature concerning 
intravascular stents in the iliac arteries has attempted 
to adhere to uniform reporting practices, many re- 
ports are based solely on clinical limb status (degree 
of  chronic lower extremity ischemia) alone; no large 
series have been reported on the basis of the strict 
hemodynamic criteria (ABI and TBI) that have been 
used to evaluate the results of  surgical revasculariza- 
tion. We have, therefore, attempted to analyze our 
results using clinical, hemodynamic, and angio- 
graphic data that may, in aggregate, give a more 
realistic appraisal of the results of PTA and primary 
stenting of the iliac arteries. 
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Fig. 4. Patency of iliac arteries according to angiographic follow-up on 101 arteries with 19 
failures. 
Table VI. Complications of iliac PTA and 
primary stenting (312 procedures) 
Complication n (%) 
Target vessel thrombosis 7 (2,2) 
Arterial dissection 5 (1,6) 
Distal embolization 1 (0,3) 
Vessel perforation 1 (0.3) 
Hemorrhage requiting transfusion 4 (1.3) 
Groin hematoma 1 (0.3) 
Groin infection 4 (1.3) 
Femoral false aneurysm 9 (2.9) 
Myocardial infarction 1 (0.3) 
Stroke 1 (0.3) 
Renal failure 9 (2.9) 
Death 1 (0.3) 
Total 44 (14.1) 
Arteriography retains its importance for evaluat- 
ing patency of iliac artery interventions; but it is 
obviously not feasible to perform invasive studies in 
all patients imply to determine stent patency. Nev- 
ertheless, a small number of patients are available 
who have undergone follow-up angiographic studies 
for evaluation of recurrent stenosis within the stent 
or for progression of disease lsewhere. Thus angio- 
graphic patency may actually underestimate the 
"true" patency rate, however, because a dispropor- 
tionate number of patients who have restenosis are 
likely to be included in this group. Clinical and non- 
invasive hemodynamic methods of determining the 
patency of stents are indirect and also have their 
shortcomings. Palpation of the ipsilateral femoral 
pulse is subjective, and the pulse may be present even 
in cases of complete iliac artery occlusion when col- 
lateral flow is abundant. Although segmental limb 
pressure measurements are an objective means of 
determining patency, they also have liabilities when 
used to evaluate procedures on the aortoiliac seg- 
ment. Measurement of the ABI is subject o misin- 
terpretation with respect to patency of iliac interven- 
tions in the presence of infrainguina! occlusive 
disease. Although probably more accurate in assess- 
ing the iliac segment, the TBI may be falsely de- 
pressed with disease of the SFA 22 and profunda fern- 
otis artery.  23 Because none of these methods of 
evaluation provides a precise determination of iliac 
stent patency, we have elected to use a number of 
criteria to help define patency, based on reporting 
standards that have been used to evaluate surgical 
procedures. >3 
The clinical patency rate (by limb status) in our 
series was 76% at 1 year and 57% at 2 years as 
determined by life table analysis. These figures are at 
the lower end of 1-year (78% to 91%) and 2-year 
(53% to 84%) patency rates reported by other au- 
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thors  17-2° and is lower than success as measured by 
objective criteria (ABI and TBI) in this report. This 
discrepancy may result from progression of infrain- 
guinal disease over time that is not significant 
enough to cause hemodynamic failure at rest (de- 
crease in hemodynamic index by 0.15 or greater, by 
definition), but enough to cause worsening of limb 
status (most commonly worsening of claudication) 
with exertion. Our reported angiographic patency 
rate (73% at 2 years) is somewhat lower than those 
found in other reports 17-19 (88% to 93% at 8.7 to 
10.4 months). This may reflect a longer follow-up 
interval, the percentage of patients with chronic oc- 
clusions (9.4%) and diffuse iliac disease (55.2% of 
patients had more than one artery treated), and, the 
number of patients for whom angiograms were ob- 
tained for suspicion ofstent failure; 19 of 101 arteries 
(18.8%) had either significant recurrent stenosis or 
occlusion or had redilatation of the stented segment 
at the time of the follow-up angiogram. 
Patency rates at 6, 12, and 24 months were 96%, 
89%, and 76% when measured by ABI. Comparative 
data are unavailable from other series that report 
stent patency. When one compares these results with 
those of PTA alone as reported by Johnston et al.,12 
who required improvement in both clinical imb sta- 
tus and ABI for success, our results eem to be better 
(89% vs 78% at 1 year, 76% vs 69% at 2 years) even if 
initial failures are excluded from the PTA group for 
both stenoses and occlusions, 16 as they are in our 
series. When evaluated by TBI, the patency rates 
were 98%, 93%, and 84% at 6, 12, and 24 months, 
respectively. Not surprisingly, these figures are some- 
what higher than those reported for ABI, as the 
recording cuff is closer to the stented segment and 
therefore influenced less by infrainguinal occlusive 
disease. Determination of patency by this hemody- 
namic method may actually be a more accurate deter- 
mination ofpatency, 3 even given its potential inaccu- 
racies in the presence of SFA and profunda femoris 
disease, as described above. 
We evaluated several factors with respect o their 
impact on initial and late failure. Factors associated 
with initial failure included a higher level of baseline 
ischemia (reflecting multilevel disease), advanced 
age, and an occluded ipsilateral SFA. These variables 
have also been implicated in initial failure of angio- 
plasty alone. 16'24'2s Despite adequate correction of 
the iliac inflow lesion at the time of intervention, this 
improvement may not always have been transmitted 
to the thigh or ankle level in the presence of multi- 
level occlusions. A higher degree of initial stenosis 
and diffuse iliac disease, as reflected by the need for 
multiple stents, were associated with initial success. 
This may reflect a greater change in flow across the 
stented segment after intervention i  patients with 
more severe iliac disease, producing significant im- 
provement when measured objectively, especially in 
the presence of a patent ipsilateral SFA. These factors 
were not associated with late success or failure. 
SFA occlusion was associated with late failure, 
and the status of the SFA outflow seems to be the 
most important variable we studied with respect o 
success or failure. Occlusion of the SFA was found to 
be consistently associated with early and late failure; 
the converse is also true, in that patency of the SFA 
can be expected to enhance success when measured 
clinically and hemodynamically. Those patients with 
infrainguinal disease, especially those who have more 
advanced egrees of baseline ischemia, may be best 
served with immediate distal surgical reconstruction, 
because they can not be expected to obtain signifi- 
cant benefit from iliac stenting alone. On the basis of 
these results the surgeon can proceed confidently 
with a distal bypass, using the iliac stent procedure as 
a reliable and durable source of inflow. 
Diabetes mellitus, female gender, and the pres- 
ence of an iliac artery occlusion (compared with ste- 
nosis) were not associated with either early or late 
failure, unlike previous series that reported angio- 
plasty alone.12-17 When comparing site of dilatation, 
there was no significant difference between the com- 
mon and external i iac arteries, although procedures 
on the external i iac approached the significance l vel 
ofp = 0.01 for late failure as measured by TBI. This 
may represent an advantage of stenting over angio- 
plasty alone, provided our results are reproducible 
elsewhere. 
CONCLUSION 
PTA and primary stenting of the iliac arteries can 
be performed safely and with reasonable arly and 
late patency rates; the results eem to be an improve-- 
ment over those of balloon angioplasty alone when 
compared with previous reports. Patency of the ipsi- 
lateral SFA is the most consistent determinant of 
early and late success by both hemodynamic and 
clinical criteria. 
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DISCUSSION 
Dr. Tony  Stanson (Rochester, Minn.). I find this 
paper to be very interesting from a pathfinding nature 
because it involves the use of primary stenting rather than 
selective stenting. Primary stenting is not what we have 
accepted conventionally as how to use stents, but perhaps 
this paper will have an impact on the future use of stents in 
the iliac arteries. There have been comments made recently 
that perhaps there would be an increase in durability of 
using stents primarily as opposed to primary balloon angio- 
plasty and selective stent placement when deemed neces- 
sary. Perhaps there is a 10% advantage, from the durability 
standpoint, of  using a stent. 
Conventionally, we place a stent primarily if there is a 
recurrent lesion or if we recanalize an iliac artery occlusion: 
The common iliac artery is considered the best segment to 
stent because of  durability. The results of  this study show, 
in comparison with Dr. Johnson's study out of Toronto, 
about 10% to 15% or more improvement in outcome than 
the balloon angioplasty study of  several years ago. How- 
ever, it is difficult to compare old studies with current ones 
because the selection of  the patient is critical. I would 
imagine that 10 years ago, how we chose which patient o 
take on with a balloon catheter alone was different, and we 
were more restrictive than we are today when you know 
you have a stent. When you perform a balloon-catheter 
procedure, with or without stent availability, the morpho- 
logic features of the lesion are also important in determin- 
ing outcome. You can almost predict the outcome if you 
can so specifically choose which cases to take for balloon 
angioplasty and which ones to send to surgery. 
The weakness of  this paper is that it is not a random- 
ized study. I would say that to have one center with such a 
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huge experience, that to have randomly picked the balloon 
alone against the stem would have been a more valuable study 
to have here, and perhaps oon the authors will mldertake 
something like that. I think it is also important to know what 
the selection criteria were for choosing apatient in this study, 
especially if we are going to determine whether using a stent is 
better than using a balloon alone. Also, what were the technb 
cal failures? There are always technical failures. Who were 
they? How did this hffluence the selection and outcome. 
I have three questions for the authors. First, because 
the outcome is so dependent on patient selection for bal- 
loon angioplasty, and I presume it is also for stenting, how 
were these patients elected? How did you determine that 
an intervention of this nature should be performed as 
opposed to surgery? 
Second, because the patient comes to us for a clinical 
problem, what is the value of studying the hemodynamics 
and angiographic appearance in determining outcome for 
this procedure as opposed to the clinical limb status alone? 
Third, because we can no longer plan to work and live 
in an cconomic vacuum, please comment about the cost- 
benefit ofstenting and surgery, especially in view of the fact 
that you have a high clinical failure rate judging by limb 
status and in view of the fact that we are dealing with a 
progrcssive disease ntity. How will you select which treat- 
ment o fit your next patient? 
I am pleased to see this large study of iliac stenting 
from a vascular medicine and vascular surgical group. This 
will further enhance the credibility of this procedure. And 
it is good to see it presented at this meeting. 
Dr. Timothy M. Sullivan. We acknowledge that this 
study is by no means perfect and that there are certain flaws 
with it and its design. It is a retrospective r view. We have 
not reported on an intent-to-treat basis, but I think that 
this study does give us a baseline as to what to expect from 
primary stenting. As you noted, patient selection is para- 
mount in interpreting the results of these procedures, and 
there is no doubt that primary stenfing allows us to treat 
more complex lesions than were treated with PTA in the 
past. Some factors to consider when trying to decide 
whether tO place a stent or stents or send your patient o 
the operating room include comorbid medical conditions. 
Patients who have severe comorbid medical conditions are 
best, at least initially, treated with a less-invasive procedure 
such as PTA and primary stenting. There are certain ana- 
tomic conditions that I think preclude the use of stcnts, 
including concomitant aneurysmal disease, ulcerative ath- 
erosclerosis that is likely to embolize at the time of inter- 
vention, and diffuse disease that extends into the common 
femoral artery or extends cephalad into the aorta. Those 
patients who have these comorbid conditions hould be 
referred for surgical intervention. 
Realizing that this procedure isnot likely as durable as 
aortobifemoral bypass grafting, I think that patients with 
claudication who fail an exercise program can go on to 
angioplasty and primary stenting. The success rates are 
acceptable, and the procedure doesn't burn any bridges; 
the converse cannot be said for aortobifemoral bypass 
grafting procedures. I think that success depends in part on 
the aggressiveness of the interventionalist performing the 
procedure. If one is extremely aggressive, one can treat a 
lot of disease but perhaps not appropriately so. I think that 
interventionalists who arc clinically trained in vascular dis- 
ease, especially vascular surgeons, can offer their patients 
either an intervention oran operation and not have to rely 
on one method or another. If one's only tool is a hammer, 
everything looks like a nail. 
In regard to your second question, you make a good 
point in that patients come to us with symptoms, not 
numbers like ankle-arm indexes. I think that we can sepa- 
rate patients into those who come with claudication as 
their indication for intervention and those who have ad- 
vanced ischemia s the indication for their intervention. 
For patients who have claudication, I think we can say on 
the basis of these preliminary results that the iliac proce- 
dure is likely to be durable but that the long-term result is 
primarily going to be influenced by the status of the ipsilat- 
eral SFA (which in some studies has been shown to throm- 
bose at 16% per year when observed out to 3 years.) The 
intervention may be durable, but the patient's ymptoms 
may recur because of progression of the disease. For pa- 
tients who have advanced ischemia, we see from these 
results that that is a predictive factor in initial failure. These 
are the patients with multilevel disease who may then 
require a distal revascularization for limb salvage, and I 
think that on the basis of these results the surgeon can do 
so confidently using the proximal iliac intervention asin- 
flow. 
Finally, related to cost, we have looked at this and 
found that bilateral iliac artery stenting compared with 
aortobifemoral bypass grafting is about one-third the 
cost--S10,000 compared with about $30,000. They are 
significantly less expensive in the short-term, but in the 
long-term may be equivalent with regard to durability of 
procedure. 
